- Home
- CBZ vs MLTX Comparison
CBZ vs MLTX Comparison
Compare CBZ & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBZ
- MLTX
- Stock Information
- Founded
- CBZ 1987
- MLTX 2021
- Country
- CBZ United States
- MLTX Switzerland
- Employees
- CBZ N/A
- MLTX N/A
- Industry
- CBZ Business Services
- MLTX Biotechnology: Pharmaceutical Preparations
- Sector
- CBZ Consumer Discretionary
- MLTX Health Care
- Exchange
- CBZ Nasdaq
- MLTX Nasdaq
- Market Cap
- CBZ 3.5B
- MLTX 2.8B
- IPO Year
- CBZ N/A
- MLTX N/A
- Fundamental
- Price
- CBZ $55.40
- MLTX $53.26
- Analyst Decision
- CBZ
- MLTX Strong Buy
- Analyst Count
- CBZ 0
- MLTX 7
- Target Price
- CBZ N/A
- MLTX $74.83
- AVG Volume (30 Days)
- CBZ 531.0K
- MLTX 666.5K
- Earning Date
- CBZ 10-28-2025
- MLTX 11-06-2025
- Dividend Yield
- CBZ N/A
- MLTX N/A
- EPS Growth
- CBZ N/A
- MLTX N/A
- EPS
- CBZ 1.84
- MLTX N/A
- Revenue
- CBZ $2,420,673,000.00
- MLTX N/A
- Revenue This Year
- CBZ $57.54
- MLTX N/A
- Revenue Next Year
- CBZ $5.95
- MLTX N/A
- P/E Ratio
- CBZ $30.09
- MLTX N/A
- Revenue Growth
- CBZ 46.49
- MLTX N/A
- 52 Week Low
- CBZ $53.92
- MLTX $31.42
- 52 Week High
- CBZ $90.13
- MLTX $61.87
- Technical
- Relative Strength Index (RSI)
- CBZ 32.82
- MLTX 44.29
- Support Level
- CBZ $53.92
- MLTX $51.45
- Resistance Level
- CBZ $58.17
- MLTX $61.30
- Average True Range (ATR)
- CBZ 1.94
- MLTX 2.74
- MACD
- CBZ -0.51
- MLTX -0.73
- Stochastic Oscillator
- CBZ 12.03
- MLTX 17.41
About CBZ CBIZ Inc.
CBIZ Inc through its subsidiaries provides professional services advisors to middle-market businesses and organizations nationwide. Its business units have been aggregated into three practice groups: Financial Services, Benefits and Insurance Services, and National Practices. The company provides its services to various industries such as Banking & Financial Services, Commercial Real Estate, Construction, Health Care Manufacturing & Distribution NFP & Education, Private Client Services, Professional Services, Public Sector, and Technology & Life Sciences. It derives the majority of its revenues from the Financial Services segment and geographically from the United States.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.